Equity / Investment · Africa · Announced 29 Nov 2024
Afreximbank → Med Aditus Pharmaceutical Kenya
Afreximbank signed a project-preparation agreement to part-fund feasibility studies for Med Aditus's planned US$40 million, 2-billion-unit tablet and capsule plant in Kisumu, Kenya. The project is seeking full funding at AfSNET in November 2026.
Parties: Afreximbank (Egypt) → Med Aditus Pharmaceutical Kenya (Kenya)
- Deal type
- Equity / Investment
- Value
- $40m
- Territory
- Kenya (Kibos, Kisumu County); 2 billion tablets and capsules per year planned
- Therapeutic area
- Multi-therapy
- Asset
- Kisumu oral solid-dose manufacturing plant (planned)
- Announced
- 29 Nov 2024
Our analysis
Why this matters
Afreximbank and Med Aditus Pharmaceutical Kenya signed a project preparation facility heads of terms agreement during the African Sub-Sovereign Governments Network (AfSNET) conference in Kisumu, 25–27 November 2024. The agreement partly finances feasibility studies for a planned pharmaceutical plant estimated to cost US$40 million. Afreximbank's funding amount was not disclosed. The intervention falls under the bank's Africa Health Security Investment Plan.
The plant, on 10 acres in Kibos, Kisumu County, is designed to make up to 2 billion tablets and capsules a year. Target areas are non-communicable diseases (cardiovascular, diabetes, cancer), HIV, malaria, tuberculosis and neglected tropical diseases. In October 2026 the project was listed among the deals seeking funding at the sixth AfSNET Investment Conference in Calabar, Nigeria, on 12–14 November 2026.
The full analysis is free to read with a work email on this page.
Source: Africa Solutions Media Hub